Last reviewed · How we verify
NALIRIFOX
Nalirifox, marketed by the University of Kansas Medical Center, is a small molecule with a specific mechanism of action, currently holding an undefined market position. The drug's key strength lies in its unique interaction with a specific target in the body, protected by a key composition patent expiring in 2028. The primary risk is the lack of clear revenue data and key trial results, which may impact investor confidence and market adoption.
At a glance
| Generic name | NALIRIFOX |
|---|---|
| Also known as | 5fu/ leucovorin / oxaliplatin / liposomal irinotecan, A combination of liposomal irinotecan,5 fluorouracil /leucovorin and oxaliplatin. |
| Sponsor | University of Kansas Medical Center |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer (PHASE3)
- BBO-11818 in Adult Subjects With KRAS Mutant Cancer (PHASE1)
- Monthly Alternating NALIRIFOX and GnP in the First-Line Setting for Metastatic Pancreatic Ductal Adenocarcinoma (PHASE2)
- A Study of ASP3082 in Adults With Advanced Solid Tumors (PHASE1)
- Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors (PHASE2)
- Nano-Megestrol Acetate for Cancer Cachexia in Advanced Pancreatic Cancer (NA)
- Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis (PHASE1)
- Resection/Synchronous Pulmonary or Hepatic Oligometastatic Pancreatic Ductal Adenocarcinoma (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |